Andreas G. Grill is appointed President and Chief Executive Officer

February 17, 2015 (Cold Spring Harbor, NY) – DepYmed, Inc. is pleased to announce the appointment of Andreas G. Grill as President and Chief Executive Officer. Mr. Grill joins DepYmed with over 22 years of pharmaceutical industry experience encompassing executive, scientific, operational and business development roles.

Prior to joining DepYmed, Mr. Grill founded Advanced Pharmaceutical Strategies, LLC (APS) a drug product development consulting firm working with a number companies within the cancer therapeutic area. Prior to APS, Mr. Grill dedicated 20 years within Pharmaceutical Research & Development at Forest Research Institute (FRI), a subsidiary of Forest Laboratories, Inc. (FLI). Mr. Grill concluded his FRI tenure as Executive Director, Pharmaceutical Research & Development (PR&D) leading multiple research and development departments as well as global project development teams. Mr. Grill was an FLI nominated member of multiple executive committees responsible for the leadership and direction of drug product development ranging from conception through marketing registration as well as life-cycle management. His drug development portfolio comprises a broad range of pharmaceutical indications and dosage forms including: Lexapro® (escitalopram oxalate) tablets/oral solution; Namenda® (memantine HCl) tablets/oral solution; Bystolic® (nebivolol HCl) tablets; Savella® (milnacipran HCl) tablets; Namenda XR® (memantine HCl) capsules, Teflaro® (ceftaroline fosamil); Linzess® (linaclotide) capsules; Namzaric™ (a fixed-dose combination of memantine extended-release / donepezil hydrochloride) capsules. Prior to Forest, Mr. Grill served in a scientific research capacity for Pfizer, Inc., Groton, Connecticut.

“Andreas brings his extensive drug product development and pharmaceutical marketing experience to DepYmed which will be invaluable in bringing Trodusquemine and other pipeline products into the clinic and beyond, based on the exciting preclinical research conducted to date,“ said Sam Backenroth, DepYmed Director and CFO of Ohr Pharmaceutical, Inc. “Depymed’s pipeline of allosteric PTP1b enzyme inhibitors affords the promise of novel therapies in multiple therapeutic settings.”

“We are pleased to have Andreas on board to lead this effort to bring this Cold Spring Harbor Laboratory science based discovery to patients,” said Teri Willey, DepYmed Director and Vice President for Business Development and Technology Transfer at Cold Spring Harbor Laboratory.

“I have had the unique opportunity to collaborate with the DepYmed stakeholders during the past few months,” said Mr. Grill. “We are looking forward to the upcoming clinical trial to investigate the effect of Trodusquemine on HER2 positive breast cancer and developing future effective treatment options for the significant needs of oncological patients.”

Mr. Grill will also serve on the Board of Directors at DepYmed. He continues to support the scientific community as an Advisory Board Member for Stony Brook University – Institute of Chemical Biology & Drug Discovery, Advisor for the BioStrategy Sessions at SUNY Stony Brook – Center of Biotechnology, Member of the Bioscience Advisory Board for SUNY Farmingdale as well as a member of the Board of Directors for the Farmingdale College Foundation. Mr. Grill holds a Bachelor of Science in Biochemistry from Stony Brook University, Stony Brook, NY as well as Master of Business Administration from Dowling College, Oakdale, NY.

DepYmed Inc., a joint venture of Ohr Pharmaceutical, Inc. (NasdaqCM:OHRP) and Cold Spring Harbor Laboratory, developing Trodusquemine (MSI-1436), an inhibitor of the enzyme PTP1B (protein tyrosine phosphatase 1B), as a therapeutic candidate for HER2-positive breast cancer. The continued preclinical research will be conducted under the guidance of Dr. Nicholas Tonks at Cold Spring Harbor Laboratory, who discovered and is an expert on the PTP1B enzyme.

Celebrating its 125th anniversary in 2015, Cold Spring Harbor Laboratory (CSHL) has shaped contemporary biomedical research and education with programs in cancer, neuroscience, plant biology and quantitative biology and associated with over 30 science-based spin-out companies. Home to eight Nobel Prize winners, the private, non-profit Laboratory is more than 600 researchers and technicians strong. The Meetings & Courses program hosts more than 12,000 scientists from around the world each year on its campuses in Long Island and in Suzhou, China. The Laboratory’s education arm also includes an academic publishing house, a graduate school and programs for middle and high school students and teachers. For more information, visit

Ohr Pharmaceutical, Inc. (NasdaqCM:OHRP) is an ophthalmology research and development company. The company’s lead product, Squalamine, is currently being studied as an eye drop formulation in several company sponsored and investigator sponsored Phase II clinical trials for various back-of-the-eye diseases, including the wet form of age-related macular degeneration, retinal vein occlusion, diabetic macular edema, and proliferative diabetic retinopathy. In addition, Ohr has a sustained release micro fabricated micro-particle ocular drug delivery platform with several preclinical drug product candidates in development for glaucoma, steroid-induced glaucoma, ocular allergies, and protein drug delivery. The company also has a research agreement with Alcon on a sustained release program. Additional information on the company may be found at

Leave a Comment